MediciNova Inc - Asset Resilience Ratio
MediciNova Inc (MNOV) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of MediciNova Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2023)
This chart shows how MediciNova Inc's Asset Resilience Ratio has changed over time. See MNOV net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MediciNova Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MediciNova Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: MediciNova Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
MediciNova Inc Industry Peers by Asset Resilience Ratio
Compare MediciNova Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for MediciNova Inc (2003–2023)
The table below shows the annual Asset Resilience Ratio data for MediciNova Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $66.27 Million | -- |
| 2022-12-31 | 53.92% | $39.98 Million | $74.15 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $87.41 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $43.42 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $39.81 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.91 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $27.27 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $29.55 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $19.57 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $30.79 Million | -- |
| 2010-12-31 | 0.86% | $623.75K | $72.93 Million | -27.57pp |
| 2009-12-31 | 28.42% | $26.81 Million | $94.33 Million | -41.89pp |
| 2007-12-31 | 70.31% | $51.86 Million | $73.75 Million | -15.46pp |
| 2006-12-31 | 85.77% | $95.72 Million | $111.59 Million | +14.83pp |
| 2005-12-31 | 70.95% | $101.02 Million | $142.39 Million | +48.63pp |
| 2004-12-31 | 22.32% | $12.00 Million | $53.77 Million | +0.12pp |
| 2003-12-31 | 22.20% | $1.25 Million | $5.63 Million | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more